Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$3.38 +4.5%	$3.07	$2.18 ▼ $7.90	$36.59M	0.75	23,511 shs	6,261 shs
CSTL Castle Biosciences	$20.29 +1.4%	$17.99	$15.45 ▼ $35.84	$586.11M	1.1	423,238 shs	166,047 shs
FLGT Fulgent Genetics	$20.06 -0.2%	$20.09	$14.57 ▼ $25.11	$610.71M	1.03	286,818 shs	87,746 shs
GTH Genetron	$4.03	$3.98	$2.08 ▼ $4.05	$127.27M	0.51	51,662 shs	412,603 shs
VCYT Veracyte	$27.51 -0.3%	$28.10	$19.73 ▼ $47.32	$2.15B	2.07	918,675 shs	445,469 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	0.00%	+10.29%	+16.38%	-12.68%	-44.76%
CSTL Castle Biosciences	0.00%	-0.32%	+19.18%	+9.24%	-4.54%
FLGT Fulgent Genetics	0.00%	+1.93%	-5.78%	+18.98%	+0.65%
GTH Genetron	0.00%	0.00%	0.00%	-0.12%	-0.12%
VCYT Veracyte	0.00%	+0.47%	+0.81%	-4.97%	+28.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CSTL Castle Biosciences	3.0429 of 5 stars	3.5	4.0	0.0	0.0	2.6	2.5	0.0
FLGT Fulgent Genetics	3.0133 of 5 stars	2.3	1.0	0.0	4.1	0.0	3.3	0.6
GTH Genetron	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	3.6105 of 5 stars	3.4	1.0	0.0	4.3	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	0.00	N/A	N/A	N/A
CSTL Castle Biosciences	3.00	Buy	$37.00	82.40% Upside
FLGT Fulgent Genetics	2.50	Moderate Buy	$24.00	19.64% Upside
GTH Genetron	0.00	N/A	N/A	N/A
VCYT Veracyte	2.70	Moderate Buy	$40.90	48.67% Upside

Current Analyst Ratings Breakdown

Latest FLGT, BNR, VCYT, GTH, and CSTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	CSTL Castle Biosciences	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$44.00 ➝ $40.00
5/8/2025	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $42.00
5/8/2025	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $41.00
5/6/2025	FLGT Fulgent Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$16.00 ➝ $23.00
5/6/2025	CSTL Castle Biosciences	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $35.00
5/6/2025	CSTL Castle Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $37.00
5/5/2025	FLGT Fulgent Genetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$24.00 ➝ $25.00
4/9/2025	VCYT Veracyte	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $37.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$70.67M	0.51	N/A	N/A	$7.39 per share	0.46
CSTL Castle Biosciences	$332.07M	1.76	$0.98 per share	20.63	$16.28 per share	1.25
FLGT Fulgent Genetics	$292.45M	2.09	N/A	N/A	$36.92 per share	0.54
GTH Genetron	$94.34M	1.35	N/A	N/A	$2.63 per share	1.53
VCYT Veracyte	$445.76M	4.83	$1.04 per share	26.53	$15.17 per share	1.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$47.49M	-$1.89	N/A	∞	N/A	-45.41%	-38.33%	-25.34%	N/A
CSTL Castle Biosciences	$18.25M	-$0.19	N/A	N/A	N/A	-1.46%	3.41%	2.95%	8/4/2025 (Estimated)
FLGT Fulgent Genetics	-$42.71M	-$1.33	N/A	N/A	N/A	-13.94%	-2.19%	-2.02%	8/1/2025 (Estimated)
GTH Genetron	-$117.21M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	$24.14M	$0.41	67.10	38.21	N/A	7.13%	6.14%	5.60%	8/5/2025 (Estimated)

Latest FLGT, BNR, VCYT, GTH, and CSTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q2 2025	FLGT Fulgent Genetics	-$0.23	N/A	N/A	N/A	$76.21 million	N/A
6/6/2025	Q1 2025	BNR Burning Rock Biotech	N/A	-$0.17	N/A	-$0.17	N/A	$18.34 million
5/5/2025	Q1 2025	CSTL Castle Biosciences	-$0.08	-$0.20	-$0.12	-$0.90	$80.40 million	$87.99 million
5/2/2025	Q1 2025	FLGT Fulgent Genetics	-$0.18	$0.04	+$0.22	-$0.37	$71.26 million	$73.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
CSTL Castle Biosciences	N/A	N/A	N/A	N/A	N/A
FLGT Fulgent Genetics	N/A	N/A	N/A	N/A	N/A
GTH Genetron	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	N/A	3.02	2.76
CSTL Castle Biosciences	0.02	9.37	9.19
FLGT Fulgent Genetics	N/A	6.32	6.32
GTH Genetron	N/A	N/A	N/A
VCYT Veracyte	N/A	5.10	4.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
CSTL Castle Biosciences	92.60%
FLGT Fulgent Genetics	48.06%
GTH Genetron	10.74%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
CSTL Castle Biosciences	6.50%
FLGT Fulgent Genetics	31.76%
GTH Genetron	N/A
VCYT Veracyte	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	1,390	10.76 million	7.50 million	Not Optionable
CSTL Castle Biosciences	540	28.87 million	27.00 million	Optionable
FLGT Fulgent Genetics	1,010	30.44 million	20.78 million	Optionable
GTH Genetron	993	31.62 million	N/A	Not Optionable
VCYT Veracyte	790	78.32 million	77.22 million	Optionable

FLGT, BNR, VCYT, GTH, and CSTL Headlines

Recent News About These Companies

Veracyte, Inc. (VCYT) - Yahoo Finance

July 3 at 7:35 PM | finance.yahoo.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Sumitomo Mitsui Trust Group Inc.

July 1, 2025 | marketbeat.com

Veracyte (NASDAQ:VCYT) Downgraded by Wall Street Zen to "Hold"

June 29, 2025 | americanbankingnews.com

Wall Street Zen Downgrades Veracyte (NASDAQ:VCYT) to Hold

June 28, 2025 | marketbeat.com

AMI Asset Management Corp Has $1.44 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)

June 26, 2025 | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Receives $40.90 Consensus Target Price from Analysts

June 26, 2025 | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Analysts

June 23, 2025 | marketbeat.com

Veracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last year

June 20, 2025 | finance.yahoo.com

GAMMA Investing LLC Purchases 18,840 Shares of Veracyte, Inc. (NASDAQ:VCYT)

June 19, 2025 | marketbeat.com

Cathie Wood’s ARK buys BWX stock, sells Adaptive Biotech

June 18, 2025 | investing.com

Exchange Traded Concepts LLC Increases Stake in Veracyte, Inc. (NASDAQ:VCYT)

June 17, 2025 | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Assenagon Asset Management S.A.

June 14, 2025 | marketbeat.com

Veracyte (NASDAQ:VCYT) Stock Rating Upgraded by Wall Street Zen

June 14, 2025 | marketbeat.com

Veracyte (NASDAQ:VCYT) Shares Down 4.8% - Should You Sell?

June 12, 2025 | marketbeat.com

Veracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved Profitability

June 9, 2025 | msn.com

Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems

June 7, 2025 | benzinga.com

Insider Selling: John Leite Sells Shares of Veracyte Inc (VCYT)

June 6, 2025 | gurufocus.com

Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?

June 6, 2025 | msn.com

Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant

June 4, 2025 | investing.com

Veracyte (VCYT) Shares Pulled Back Despite Beating Expectations

June 3, 2025 | msn.com

Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO

May 28, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Chime’s Smart IPO: Half the Valuation, Double the Strength
By Jeffrey Neal Johnson | June 18, 2025
View Chime’s Smart IPO: Half the Valuation, Double the Strength
3 Stocks Hitting All-Time Highs With More Room to Run
By Dan Schmidt | June 27, 2025
View 3 Stocks Hitting All-Time Highs With More Room to Run
GitLab: Buy It Low While You Still Can—Higher Prices Are Coming
By Thomas Hughes | June 11, 2025
View GitLab: Buy It Low While You Still Can—Higher Prices Are Coming
3 Utility Stocks That Combine Income and Stability
By Chris Markoch | July 2, 2025
View 3 Utility Stocks That Combine Income and Stability
Alphabet’s Comeback: The Hidden Engines Powering Google
By Ryan Hasson | June 23, 2025
View Alphabet’s Comeback: The Hidden Engines Powering Google

FLGT, BNR, VCYT, GTH, and CSTL Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$3.38 +0.15 (+4.49%)

Closing price 07/3/2025 02:07 PM Eastern

Extended Trading

$3.38 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Castle Biosciences NASDAQ:CSTL

$20.28 +0.28 (+1.37%)

As of 07/3/2025 01:04 PM Eastern

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Fulgent Genetics NASDAQ:FLGT

$20.06 -0.04 (-0.20%)

Closing price 07/3/2025 02:30 PM Eastern

Extended Trading

$20.06 0.00 (0.00%)

As of 07/3/2025 04:32 PM Eastern

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Genetron NASDAQ:GTH

Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.

Veracyte NASDAQ:VCYT

$27.51 -0.07 (-0.25%)

Closing price 07/3/2025 03:36 PM Eastern

Extended Trading

$27.67 +0.16 (+0.58%)

As of 07/3/2025 04:28 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time